Jivolar

Metformin Hydrochloride and Sitagliptin, the active ingredient in Jivolar, is a Biguanide/DPP-4 inhibitor combination presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients. GNH USA supplies Jivolar as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jivolar is indicated for the management of type 2 diabetes mellitus and related glycemic abnormalities. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Inadequate glycemic control with metformin alone: provides additional glucose reduction when combined with metformin. - High HbA1c levels: helps achieve target HbA1c in patients not meeting goals with monotherapy.

Jivolar may cause a range of adverse reactions.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia. - Diarrhea: loose stools occurring especially during treatment initiation. - Headache: mild to moderate intensity. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycemia: particularly when used with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain.

Before prescribing Jivolar, clinicians should consider several safety factors. - Renal function: assess renal impairment as metformin accumulation can occur. - Hepatic function: monitor liver enzymes due to potential hepatic effects. - Cardiovascular disease: use cautiously in patients with heart failure. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia or severe infection. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Jivolar can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction and metformin accumulation. - Insulin or sulfonylureas: increase risk of severe hypoglycemia. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may affect glucose control. - Corticosteroids: can elevate blood glucose requiring dose adjustments. - NSAIDs: may impair renal function, influencing metformin clearance.